- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05492734
A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling
September 1, 2022 updated by: Edgewise Therapeutics, Inc.
A Phase 1 Study to Assess the Feasibility of Non-invasive Dried Blood Sampling for Assessment of EDG-5506 Concentrations
This is a Phase I, open-label, single-dose, 1-period study to compare EDG-5506 concentrations measured from venous and capillary blood sampling in healthy adult subjects.
EDG-5506 is an investigational product designed to selectively modulate a fast skeletal muscle motor protein called myosin that is part of the contraction machinery of the damage-prone muscle fibers.
Study Overview
Detailed Description
Ten (10) healthy, adult male and female (of non-childbearing potential only) participants will be enrolled in the single-site study.
Participants will receive a single oral dose of EDG-5506 on Day 1.
Serial blood sampling will be collected pre-dose and up to 26 hours post-dose using venous blood sampling by venipuncture and capillary blood sampling by a capillary blood self-sampling device.
On Day 3, participants will self-collect a capillary blood sample at home.
The final on-site visit will be on Day 7 when a last blood sample will be collected using venous blood sampling by venipuncture and capillary blood sampling by a capillary blood self-sampling device.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68502
- Celerion, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy, adult, males or females, aged 19-55 years (inclusive) at the Screening visit.
- Females must be of non-childbearing potential. Males with female partners must use a medically accepted contraceptive regimen or abstain from sexual intercourse for 90 days after dosing.
- Non-smoker and must not have used any tobacco products within 3 months prior to the Screening visit.
- Body weight greater than 50 kg and body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive at the Screening visit.
- Medically healthy with no clinically significant findings for oculofacial and proximal limb strength assessments and swallowing function assessment, medical history, physical examination, laboratory profiles, vital signs, and ECGs.
Exclusion Criteria:
- History of, or physical examination findings indicating clinically significant endocrine, neurological, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases that, in the opinion of the PI, would render the subject being unsuitable for the study.
- Female participants with a positive pregnancy test at the screening visit or are lactating.
- Poor venous access and/or cannot tolerate venipuncture.
- Unable to refrain from or anticipates the use of any drugs (including prescription and non-prescription medications, herbal remedies, vitamin supplements, or grapefruit/Seville orange containing products) beginning 14 days prior to dosing. Any drugs known to be moderate or strong inducers of CYP3A4 enzymes cannot be used within 28 days prior to dosing.
- Participation in any other investigational drug study within 30 days prior to dosing.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment
Drug: EDG-5506
|
single oral dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in area under the concentration-time curve (AUC0-24, AUC0-26, AUC0-144 and AUC0-t) measurements for EDG-5506 in blood collected by capillary blood self-sampling versus venous blood sampling
Time Frame: 7 days
|
7 days
|
Plasma maximum measured drug concentration (Cmax) measurements for EDG-5506 in blood collected by capillary blood self-sampling versus venous blood sampling
Time Frame: 7 days
|
7 days
|
Time of maximum concentration (Tmax) measurements for EDG-5506 in blood collected by capillary blood self-sampling versus venous blood sampling
Time Frame: 7 days
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the concentration-time curve (AUC0-24, AUC0-26, AUC0-144 and AUC0-t) measurements for EDG-5506 in plasma.
Time Frame: 7 days
|
7 days
|
Plasma maximum measured drug concentration (Cmax) measurements for EDG-5506 in plasma.
Time Frame: 7 days
|
7 days
|
Time of maximum concentration (Tmax) measurements for EDG-5506 in plasma.
Time Frame: 7 days
|
7 days
|
Incidence of treatment-emergent adverse events
Time Frame: 7 days
|
7 days
|
Incidence of abnormal clinical laboratory test results
Time Frame: 7 days
|
7 days
|
Incidence of abnormal vital signs
Time Frame: 7 days
|
7 days
|
Incidence of abnormal electrocardiograms (ECGs)
Time Frame: 7 days
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 12, 2022
Primary Completion (ACTUAL)
August 19, 2022
Study Completion (ACTUAL)
August 19, 2022
Study Registration Dates
First Submitted
August 5, 2022
First Submitted That Met QC Criteria
August 5, 2022
First Posted (ACTUAL)
August 8, 2022
Study Record Updates
Last Update Posted (ACTUAL)
September 2, 2022
Last Update Submitted That Met QC Criteria
September 1, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EDG-5506-104
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscular Dystrophies
-
Assistance Publique - Hôpitaux de ParisRecruitingLimb Girdle Muscular DystrophiesFrance
-
aTyr Pharma, Inc.CompletedLimb-Girdle Muscular Dystrophies | Facioscapulohumeral Muscular DystrophyUnited States, Denmark, France
-
Wake Forest University Health SciencesMuscular Dystrophy AssociationCompletedMuscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED)United States
-
Virginia Commonwealth UniversityWashington University School of Medicine; University of Iowa; University of Minnesota and other collaboratorsRecruitingMuscular Dystrophies | Limb Girdle Muscular DystrophyUnited States, United Kingdom
-
Sarepta Therapeutics, Inc.Active, not recruiting
-
ML Bio Solutions, Inc.Virginia Commonwealth UniversityCompletedMuscular Dystrophies | Limb Girdle Muscular DystrophyUnited States, Denmark
-
Neurogen Brain and Spine InstituteWithdrawn
-
Rigshospitalet, DenmarkRecruitingLimb Girdle Muscular DystrophyDenmark
-
Sarepta Therapeutics, Inc.RecruitingLimb-girdle Muscular DystrophyUnited States
-
Rigshospitalet, DenmarkCompleted
Clinical Trials on EDG-5506
-
Edgewise Therapeutics, Inc.CompletedNervous System Diseases | Genetic Diseases, Inborn | Musculoskeletal Diseases | Muscular Diseases | Neuromuscular Diseases | Muscular Dystrophies | Muscular Disorders, Atrophic | Healthy VolunteerUnited States
-
Edgewise Therapeutics, Inc.RecruitingDuchenne Muscular DystrophyUnited States
-
Edgewise Therapeutics, Inc.Medpace, Inc.Enrolling by invitationBecker Muscular DystrophyUnited States, Netherlands
-
Edgewise Therapeutics, Inc.Medpace, Inc.; SYSNAV; ImagingNMDRecruitingBecker Muscular DystrophyUnited States, Netherlands, United Kingdom
-
Edgewise Therapeutics, Inc.RecruitingDuchenne Muscular DystrophyUnited States
-
Edgewise Therapeutics, Inc.Medpace, Inc.CompletedBecker Muscular DystrophyUnited States
-
Edgewise Therapeutics, Inc.Worldwide Clinical TrialsCompletedBecker Muscular Dystrophy | Healthy VolunteerUnited States
-
Edgewise Therapeutics, Inc.Recruiting
-
Edgewise Therapeutics, Inc.RecruitingHypertrophic CardiomyopathyUnited States
-
Hospices Civils de LyonCompleted